This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After Plunging 30.3% in 4 Weeks, Here's Why the Trend Might Reverse for Semler Scientific Inc. (SMLR)
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Semler Scientific Inc. (SMLR) Q3 Earnings Beat Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 24.32% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips
by Zacks Equity Research
The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.
Here's Why Investors Should Hold Exact Sciences (EXAS) Stock
by Zacks Equity Research
Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.
3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout
by Zacks Equity Research
McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.
Zacks Industry Outlook Highlights ShockWave Medical, Semler Scientific and Asensus Surgical
by Zacks Equity Research
ShockWave Medical, Semler Scientific and Asensus Surgical are part of Zacks Industry Outlook article.
3 Medical Instruments Stocks to Buy Despite Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on R&D investments. SWAV, SMLR and ASXC are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is disrupting the trend.
Semler Scientific Inc. (SMLR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 27.50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Surges 3.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Penumbra (PEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in EDAP TMS S.A. (EDAP): Can Its 13.4% Jump Turn into More Strength?
by Zacks Equity Research
EDAP TMS S.A. (EDAP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Semler Scientific Inc. (SMLR) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of -19.61% and 5.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 12.20% and 19.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Semler Scientific Inc. (SMLR) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of -21.54% and -10.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Adds New Products to Omni Hysteroscopy Offering
by Zacks Equity Research
Hologic (HOLX) expands Omni suite in EMEA with the new Omni 30 degree hysteroscope, Omni Lok cervical seal and Omni 5 French seal products.
Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle
by Zacks Equity Research
Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.
Thermo Fisher (TMO) Launches Kit for Safer Sample Collection
by Zacks Equity Research
Thermo Fisher (TMO) launches SpeciMAX Stabilized Saliva Collection Kit that can support global efforts toward SARS-CoV-2 research by ensuring safer saliva collection.
Globus Medical (GMED) Progresses With ExcelsiusGPS in DBS
by Zacks Equity Research
According to Globus Medica (GMED), the clinical superiority of ExcelsiusGPS continues to be recognized by surgeons.
Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants
by Zacks Equity Research
Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.
Semler Scientific Inc. (SMLR) Surges 11.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Semler Scientific Inc. (SMLR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NEOGEN (NEOG) Igenity Branded Calves Score Highest US Sales
by Zacks Equity Research
NEOGEN's (NEOG) Igenity-tested calves earn an average premium of over $59 in the summer selling season.
Thermo Fisher's (TMO) Delta Q IRMS to Back Sustainable Science
by Zacks Equity Research
Thermo Fisher (TMO) has introduced the new Delta Q IRMS under the IsoFootprint campaign to support sustainable science by eliminating carbon dioxide emission.